This page shows the latest Mvasi news and features for those working in and with pharma, biotech and healthcare.
For Amgen it is its second biosimilar product approval in Europe after Mvasi (bevacizumab), a version of Roche’s cancer drug Avastin.
Amgen and Allergan’s Mvasi biosimilar was cleared by the FDA last September, while Boehringer Ingelheim, Samsung Bioepis, Pfizer and Biocon/Mylan also have biosimilars in late-stage development.
year. Avastin (bevacizumab), Roche’s biggest-selling cancer drug, will imminently face some stiff competition in the EU from Amgen and Allergan’s recently licenced biosimilar Mvasi - which became the first
Mvasi, their version of Roche's blockbuster, is licensed for six types of cancers. ... The approval was based on data showing Mvasi and beveacizumab are highly similar, with no clinically meaningful differences in terms of efficacy, safety and
cancer antibody after Amgen and Allergan got a green light for their Mvasi biosimilar of Roche’s Avastin (bevacizumab) in September.
The FDA green light for Mvasi (bevacizumab-awwb) covers most of the approved indications for Avastin (bevacizumab), which include certain patients with colorectal, lung, brain, kidney and cervical cancers, setting up ... In July, the FDA's Oncologic
More from news
Approximately 3 fully matching, plus 3 partially matching documents found.
We love what we do and we think it shows.It shows in the work we do, the space we work...